non-small cell lung cancer
In a Phase I study presented at AACR's annual meeting, 71 percent of patients who hadn't received a prior anti-HER2 ADC responded to the drug.
The RAS(ON) inhibitor shrunk tumors in around 60 percent of patients with KRAS G12D mutations, according to a study presented at AACR's annual meeting.
Amid an 18 percent increase in cancer drug sales, J&J executives shared hopes that recent overall survival data for the drug combo will be practice changing.
European Commission Approves J&J's Subcutaneous Rybrevant for Certain NSCLC Patients
The commission approved the new formulation in first- and second-line NSCLC settings, in which intravenous Rybrevant is already available.
CureVac to Initiate Phase I Trial of mRNA Immunotherapy in NSCLC
The firm will evaluate CVHNLC in combination with Keytruda as a first-line and first-line maintenance treatment in NSCLC.